Day-one subcutaneous Leqembi means starting lecanemab treatment with weekly skin injections instead of IV infusions. Lecanemab is an anti-amyloid drug for early Alzheimer's, which means mild cognitive impairment or mild dementia due to Alzheimer's with confirmed amyloid buildup. According to the Eisai/Biogen press release, FDA approved LEQEMBI IQLIK as an initiation dose for early Alzheimer's disease on July 13, 2026 the FDA approval notice. The questions below help caregivers check eligibility, home injection training, brain-swelling risk, and follow-up care with a specialist.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who still qualifies for the starter injections?
- What does the at-home start actually involve?
- What should you ask about brain swelling and bleeding risk?
- How do scheduling, pharmacy, and coverage change?
Who still qualifies for the starter injections?
Eligibility did not expand with the new starter dose. The Alzheimer's Association notes treatment remains for mild cognitive impairment or mild dementia due to Alzheimer's with confirmed elevated amyloid by PET or CSF testing the Association's lecanemab page. That rule keeps the focus narrow.
Moderate or advanced dementia does not qualify. A positive amyloid test is required, not memory symptoms alone. Ask the specialist to confirm each point before planning a start date:.
- diagnosis of mild cognitive impairment or mild dementia due to Alzheimer's
- amyloid confirmed by PET scan or spinal fluid test
- current medicines, stroke history, and bleeding risk reviewed
What does the at-home start actually involve?
Eisai/Biogen via PR Newswire describes the initiation regimen as 500 mg once weekly given as two consecutive 250-mg autoinjector injections, each delivered in about 15 seconds the company dosing announcement. That design allows treatment to begin without IV infusions. Home use does not mean the first doses happen alone. Prescribing information requires initiation under a health professional who directly supervises at least two consecutive doses.
The supervisor must confirm the patient and caregiver can inject correctly before home use. Ask who will teach the two-shot sequence, where the supervised doses occur, and what technique check must be passed. Ask how to store, handle, and dispose of autoinjectors. Bring the person who will give most shots to that training visit.
What should you ask about brain swelling and bleeding risk?
Lecanemab carries an FDA boxed warning for amyloid-related imaging abnormalities, called ARIA. According to FDA prescribing information summarized by Medical Daily, ARIA can cause brain swelling or tiny bleeds and requires a recent baseline brain MRI plus scheduled follow-up MRIs. Risk is not equal for everyone.
According to Eisai/Biogen safety disclosure, people with two copies of ApoE epsilon 4 face substantially higher ARIA rates, including symptomatic and severe swelling. ApoE epsilon 4 testing is recommended before starting to inform risk discussion. Ask whether genetic testing is done in your clinic, how results change the recommendation, and which symptoms should trigger an urgent call. Ask when the baseline MRI must occur and how many follow-up MRIs are planned during the first months.
How do scheduling, pharmacy, and coverage change?
Infusion-center booking is no longer the first step. According to Eisai/Biogen via BioSpace, the company planned U.S. commercial availability of the initiation autoinjector for late August 2026 through specialty pharmacy the BioSpace availability report. That shifts caregiver work toward training, MRI scheduling, and coverage.
Before approval, the maintenance autoinjector was only for use after 18 months of IV lecanemab every two weeks. The new starter dose removes that long IV lead-in for eligible patients. Ask which specialty pharmacy will ship the autoinjectors, who authorizes coverage, and who books MRIs and safety visits. Ask the specialty pharmacy for the trainer's direct phone number before you leave the second supervised dose.
You Might Also Like
- Tauklarify Imaging for Alzheimer’s Tau Tangles in 2026: Questions Primary Care Patients Can Bring to a Clinician
- PrecivityAD2 and Younger-Onset Alzheimer’s Diagnosis in 2026: Questions Primary Care Patients Can Bring to a Clinician
- Subjective Cognitive Decline Data for Public Health Action in 2026: What Is Established and What Remains Uncertain for Family Caregivers
